Ixekizumab (Taltz) for adults with plaque psoriasis who are unable to have a different systemic treatment

In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the advantages and disadvantages of ixekizumab (trade name: Taltz) when compared with the standard treatment for people with moderate to severe plaque psoriasis in whom a different systemic treatment didn't work well enough or wasn't possible. For the purpose of this comparison, the manufacturer provided data from 302 patients. Of these, 136 people had treatment with ixekizumab, while 166 had treatment with ustekinumab.

What are the advantages of ixekizumab?

  • Complete remission of psoriasis: The study suggests that ixekizumab has an advantage here. About 49 out of 100 people who used ixekizumab became symptom-free within the 24-week treatment. This was the case for only about 24 out of 100 people who had treatment with ustekinumab.
  • Health-related quality of life: Here, too, the study suggests that the new treatment has an advantage: 66 out of 100 people who used ixekizumab reported that their quality of life had improved, compared to only 53 out of 100 people who had the standard treatment.

What are the disadvantages of ixekizumab?

  • Side effects caused by the injection: The study suggests that ixekizumab has a disadvantage in terms of injection-related side effects. These occurred in about 19 out of 100 people who used ixekizumab, compared to only 3 out of 100 people who used ustekinumab. The typical side effects included pain or redness around the site of injection.

No difference

  • Itching and painful skin: No difference was found in terms of these symptoms.
  • General health: There was no real difference between the treatments here, either.
  • Serious side effects: Severe side effects were equally common for both treatments. About 2 to 3 out of 100 people in each group were affected.
  • Treatment stopped due to side effects: No difference was found here. About 1 to 2 out of 100 people in each group stopped the treatment.
  • Susceptibility to infections: There was no difference between the treatments here, either.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ixekizumab (Plaque Psoriasis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-07. May 30, 2017. (IQWiG reports; Volume 514).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on June 28, 2018
Next planned update: 2021

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.